- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01256450
Efficacy and Safety Study of Buprenorphine HCl Buccal Film in Subjects With Low Back Pain
A 12-Week, Placebo Controlled, Double Blind, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of Buprenorphine HCl Buccal Film in Subjects With Moderate to Severe Chronic Low Back Pain
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
This is an enriched enrollment, randomized withdrawal study with an open label, dose-titration period followed by a randomized, double-blind, placebo-controlled treatment period of 12 weeks. During the double-blind treatment period, this study will evaluate the effectiveness of buprenorphine HCl buccal film versus placebo buccal film in treating CLBP in subjects.
Buprenorphine HCl buccal film is an oral transmucosal form of the opioid analgesic, buprenorphine hydrochloride, intended for application to the buccal mucosa. Buprenorphine is a synthetic opioid that is classified as a partial µ-receptor agonist and a Schedule III controlled substance in the United States.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35209
- Alabama Orthopaedic Center - Research
-
Mobile, Alabama, Stati Uniti, 36608
- Coastal Clinical Research, Inc.
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85023
- Arizona Research Center
-
-
California
-
Fresno, California, Stati Uniti, 93710
- Neuro-Pain Medical Center
-
La Jolla, California, Stati Uniti, 92037
- University of California, San Diego Medical Center, UCSD Center for Pain Medicine
-
Long Beach, California, Stati Uniti, 90806
- Collaborative Neuroscience Network, Inc.
-
-
Florida
-
DeLand, Florida, Stati Uniti, 32720
- Avail Clinical Research, LLC
-
Jupiter, Florida, Stati Uniti, 33458
- Health Awareness, Inc.
-
Plantation, Florida, Stati Uniti, 33317
- Gold Coast Research, LLC
-
Port Orange, Florida, Stati Uniti, 32129
- Accord Clinical Research, LLC
-
-
Georgia
-
Marietta, Georgia, Stati Uniti, 30060
- Taylor Research, LLC
-
-
Illinois
-
Bloomington, Illinois, Stati Uniti, 61701
- Millennium Pain Center
-
-
Indiana
-
Evansville, Indiana, Stati Uniti, 47714
- MediSphere Medical Research Center, LLC
-
-
Kansas
-
Leawood, Kansas, Stati Uniti, 66211
- International Clinical Research Institute
-
-
Massachusetts
-
Watertown, Massachusetts, Stati Uniti, 02472
- MedVadis Research Corporation
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti, 89144
- Office of Stephen H. Miller, MD
-
-
New York
-
New York, New York, Stati Uniti, 10022
- Research Across American
-
-
North Carolina
-
Raleigh, North Carolina, Stati Uniti, 27612
- Wake Research Associates, LLC
-
Winston-Salem, North Carolina, Stati Uniti, 27103
- The Center for Clinical Research, LLC
-
-
Pennsylvania
-
Altoona, Pennsylvania, Stati Uniti, 16602
- Allegheny Pain Management
-
-
Texas
-
Austin, Texas, Stati Uniti, 78731
- FutureSearch Trials of Neurology
-
El Paso, Texas, Stati Uniti, 79902
- Southwest Urgent Care Center
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84106
- Lifetree Clinical Research
-
West Jordan, Utah, Stati Uniti, 84088
- Advanced Clinical Research
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Male or non-pregnant and non-nursing female aged 18 or older
- History of moderate to severe chronic low back pain for ≥3 months with a pain intensity ≥5 [11 point numerical rating scale] reported at the open-label titration period Day 0/1 visit following a washout period (opioids, nonsteroidal anti-inflammatory drugs [NSAIDs], and muscle relaxants) of approximately 12 to 24 hours
- Currently taking ≤60 mg oral morphine/day or equianalgesic dose of another opioid (including opioid naïve) for 1 week or longer
- Stable health, as determined by the Investigator, on the basis of medical history, physical examination, and screening laboratory results so as to comply with all study procedures
- Female subjects of childbearing potential must be using a recognized effective method of birth control
- Written informed consent obtained at Screening, prior to any procedure being performed
Exclusion Criteria:
- Reflex sympathetic dystrophy or causalgia (complex regional pain syndrome), acute spinal cord compression, cauda equina compression, acute nerve root compression, meningitis, and discitis
- Surgical procedure for back pain within 2 months prior to screening or nerve/plexus block within 4 weeks of screening
- Hypokalemia or clinically unstable cardiac disease, including: unstable atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, or active myocardial ischemia
- Corrected QT (QTc) interval of >450 milliseconds on the 12-lead electrocardiogram (ECG)
- History of long QT syndrome, or an immediate family member with this condition
- Diagnosis of moderate to severe hepatic impairment.
- History of severe emesis with opioids
- Clinically significant sleep apnea
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: BEMA Buprenorfina
film buccale solubile di buprenorfina
|
buccal soluble film; applied to the buccal mucosa twice daily
Altri nomi:
|
Comparatore placebo: BEMA Placebo
placebo buccal soluble film
|
buccal soluble film; applied to the buccal mucosa twice daily
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change in Pain Intensity From Baseline to Week 12
Lasso di tempo: Baseline, Week 12
|
Change in pain intensity = average of daily pain scores from the last 7 days prior to week 12 visit - average of daily pain scores for the last 7 days prior to randomization.
Average pain intensity over the last 24 hours was rated on an 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst pain imaginable).
|
Baseline, Week 12
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Passaggio dal basale alla settimana 12 nel questionario sulla disabilità di Roland Morris
Lasso di tempo: Basale, settimana 12
|
I soggetti valutano la disabilità dovuta al mal di schiena utilizzando il Roland Morris Disability Questionnaire (RMDQ) composto da 24 dichiarazioni di disabilità.
Il punteggio del RMDQ è il numero totale di elementi controllati, che va da 0 a 24 con punteggi più alti che indicano una maggiore disabilità.
|
Basale, settimana 12
|
Change From Baseline in Pain Intensity Over Time Using NRS Scale
Lasso di tempo: Baseline; Day 14, Day 28, Day 42, Day 56, Day 70, and Day 84
|
Change in pain intensity = average of daily pain scores from the last 7 days prior to each visit - average of daily pain scores for the last 7 days prior to randomization.
Average pain intensity over the last 24 hours was rated on an 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst pain imaginable).
|
Baseline; Day 14, Day 28, Day 42, Day 56, Day 70, and Day 84
|
Number of Participants With Response to Treatment as Assessed by an NRS Scale
Lasso di tempo: Week 12
|
Responses are defined as the relative improvement in pain score at week 12 from baseline, calculated from ratings of average pain intensity over the last 24 hours on an 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst pain imaginable).
|
Week 12
|
Percentage of Participants With Treatment Failure in the Double-blind Treatment Phase (up to 12 Weeks)
Lasso di tempo: Baseline to treatment failure or end of double-blind treatment phase (up to 12 weeks)
|
Treatment failure is defined as study discontinuation due to lack of efficacy or due to adverse event in the double-blind treatment phase.
|
Baseline to treatment failure or end of double-blind treatment phase (up to 12 weeks)
|
Subject Impression of Change in Pain Intensity From Baseline to Week 12 Using PGIC Scale
Lasso di tempo: Baseline, Week 12
|
Subjects assessed changes in activity, limitations, symptoms, and overall quality of life related to their painful condition since beginning treatment using the Patient Global Impression of Change (PGIC), a balanced 7-point scale from 1 (no change or condition got worse) to 7 (a great deal better and considerable improvement that has made all the difference).
|
Baseline, Week 12
|
Change From Baseline to Week 12 in Treatment Satisfaction Using TSQM
Lasso di tempo: Baseline, Week 12
|
The Treatment Satisfaction Questionnaire for Medication (TSQM) is a 14-item instrument used to assess the subject's satisfaction with the ability of the study medication to prevent or treat the condition of chronic low back pain (CLBP) for effectiveness, side effects, convenience, and global satisfaction.
Scores range from 0 to 100, where a higher score indicates less dissatisfaction (ie, greater satisfaction).
|
Baseline, Week 12
|
Change From Baseline to Week 12 in Subject's Overall Satisfaction With Study Drug
Lasso di tempo: Baseline, Week 12
|
Subjects were asked to rate their overall satisfaction with their study drug on a 5-point scale ranging from 1 (poor) to 5 (excellent).
|
Baseline, Week 12
|
Change From Baseline to Week 12 in Investigator's Overall Satisfaction With Study Drug
Lasso di tempo: Baseline, Week 12
|
Investigators rated their overall satisfaction with the study drug administered to a given subject on a 5-point scale ranging from 1 (poor) to 5 (excellent).
|
Baseline, Week 12
|
Use of Rescue Medication
Lasso di tempo: Day 7, 14, 28, 42, 56, 70, 84, and 91 within double-blind treatment phase
|
Calculated from the use of rescue medication recorded in subject diary as the sum of all rescue medication tablets used in the last 7 days previous to the derived visit, divided by the number of days in this duration where the amount was reported.
|
Day 7, 14, 28, 42, 56, 70, 84, and 91 within double-blind treatment phase
|
Collaboratori e investigatori
Investigatori
- Direttore dello studio: Andrew Finn, PharmD, BioDelivery Sciences International, Inc.
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- BUP-301
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Dolore
-
University of OklahomaThe Children's Hospital at OU Medical CenterCompletatoDolore addominale funzionale | Crisi falciforme | Pazienti seguiti dal Pain Team